Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info

Incidence of Severe Outcome in Rheumatoid Arthritis During 20 Years

JUHA K. JÄNTTI, KALEVI KAARELA, EERO A. BELT, and HANNU J. KAUTIAINEN

ABSTRACT.

Objective.
Information from successive inception cohorts is needed to reveal changes in the endpoint severity of rheumatoid arthritis (RA). We assessed joint destruction and disability 8-20 years after the onset of RA to estimate the number of patients with severe disease at the endpoint.

Methods. Radiographs of the hands and feet were taken at onset and at 1, 3, 8, 15, and 20 years from entry among 103 patients with recent onset (< 6 mo) seropositive RA. The Larsen score of 0-100 of 20 joints of hands and feet, the Health Assessment Questionnaire (HAQ) index, and the number of large joint arthroplasties were used to assess severity. The cumulative number of patients with amyloidosis was recorded.

Results. The median progression of small joint destruction was 2-3% yearly. At the endpoint 36% of the patients had Larsen score 50-100 and 23% scored 67-100. The endpoint HAQ index was 2-3 in 16% of the 81 patients investigated. The number of large joint arthroplasties was 29 in 16 patients. A high Larsen score or HAQ was registered in 30 (29%) patients. The incidence of amyloidosis was 13.6%; at the end of the 20 year followup 9 of the 14 patients with amyloidosis had died.

Conclusion. Our prospective 20 year RA study is the first epidemiological survey in which 20 year severity in RA has been determined by 4 clinical measures; these data will serve as a basis for discussion of methods and comparison with other cohorts in the future. (J Rheumatol 2002; 29:688-92)

Key Indexing Terms:

RHEUMATOID ARTHRITIS
RADIOGRAPHS
OUTCOME
HEALTH ASSESSMENT QUESTIONNAIRE
SEVERITY



Return to April 2002 Table of Contents



© 2002. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.